Antidepressants shown worthless for most consumers
The comments below expand upon an Infomail about the recently published JAMA meta-analysis.
Letter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
The Damaging Impact of PDUFA and Why It Should be Repealed
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
Eli Lilly Lies About Zyprexa_NYT Editorial Calls for CongressionalHearings
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
Concealed Paxil Suicide Data Released after years under Court Seal
Dr. Peter Breggin’s sealed expert medical report in a Paxil liability case is now in the public domain.